ABSTRACT SUBMISSION FORM

Please tick (√) the appropriate box: ☐ Invited speaker ☐ Oral presenter ☐ Poster presenter

Title of Abstract	

Discipline *(please tick one)*

- ☐ **Biosafety and Biosecurity**
- ☐ **Clinical Biochemistry**
- ☐ **Cytology and Histology**
- ☐ **Haematology and Transfusion Medicine**
- ☐ **Immunology**
- ☐ **Laboratory Genetics and Genomics**
- ☐ **Laboratory Management**
- ☐ **Microbiology and Parasitology**
- ☐ **Molecular Diagnostics**
- ☐ **Virology**
- ☐ **Others, please specify** _____

Principal Author	**Presenting Author**
Name:	**Name:**
Current Position:	**Current Position:**
Department:	**Department:**
Organisation:	**Organisation:**
Email:	**Email:**
Tel:	**Tel:**

Declaration

Conflict of Interest Statement

Please tick (√) the appropriate box below		**Signature and Date**
	The author(s) declare(s) that there is no conflict of interest.	
	The author(s) declare(s) that there is a potential conflict of interest.	

If there is potential conflict of interest, please state:

Type of interest, e.g. shares, employment, payment (including details on any work, etc.)	Name of entity	Relationship with the entity	Current interest? (or date ceased)

Guidelines For Abstract Preparation

Language	Abstract must be written and presented in English.
Title	Title of abstract should not exceed 30 words. Do not use abbreviations in the title.
Name	The authors are to write their name as Given name, Surname/Family name (e.g. Yun Fatt, Chow; Aminah Ahmad; Bhavani Muthusamy; Francis Light). Do not include titles and degrees. Please bold the name of the presenter.
Institution	List the author's institution by department, institution, city and country.
Abstract words	Abstract is to have 200-300 words.
Abstract body	Abstract is to have an introduction/aim, method, results, and conclusion.
Abbreviations	Define the abbreviation in the first use.
Data units	Data units must be in the International System of Units (SI units).
Keywords	Keywords must not be less than 3 words and not more than 5 words. Arrange the keywords in alphabetical order.
Font	Abstract to use font Times New Roman with a font size of 12 points.
Reproduce	Abstract reproduced will be as is submitted with no editing. The author is responsible for all spelling, grammatical or scientific errors.
Conflict of interest	The author must disclose conflict of interest to avoid any commercial bias.
Copyright	By submitting the abstract, the author grants the AAMLS 2023 the exclusive right to first publish the abstract and thereafter a non-exclusive right to publish, display and store the abstract in all forms, formats, and media. No fees shall be paid to the author by AAMLS 2023 for the license granted herein. The author will retain the copyright of his or her abstract as well.
Withdrawal	Authors who wish to withdraw their abstract must send a written request to the Scientific Committee at **mimlsabs09@yahoo.com**

Abstract Review and Selection

Authors are encouraged to submit full paper and if selected by the Editorial Board, will be published as proceedings in the Malaysian Journal of Medical Laboratory Sciences (MJMLS).

The AAMLS 2023 Scientific Committee reserves the right to select papers relevant to the session. Presenters may present papers without having their papers published in congress proceedings or MJMLS.

Important Dates

Abstract Submission Deadline	**31 July 2023**
Presenter Registration Deadline	**31 August 2023**
Presentation File Submission Deadline	**8 September 2023**

Use the following excerpt as a format guide:

INVESTIGATION OF THE CHROMOSOME 6 INSTABILITY AND THE MAPK SIGNALING PATHWAYS IN HUMAN OSTEOSARCOMA

[1] M. Rozi Ramli, [2] **M.M. Hamdi**, [3]Mohd Aminudin Mustapha
[4]Mohamad Zulkarnaen Ahmad Narihan

[1]Department of Pathology, Sarawak General Hospital (SGH), Jalan Hospital (SGH), Jalan Hospital, 93586 Kuching, Sarawak.
[2]Department of Para-Clinical Science, Faculty of Medicine and Health Sciences (FMHS), UNIMAS, 94300 Kota Samarahan, Sarawak.
[3]Pre-University Centre, UNIMAS,94300 Kota Samarahan, Sarawak.
[4]Department of Pathology, FMHS, UNIMAS, 94300 Kota Samarahan, Sarawak.

*Presenter's email: mmhamdi@fmhs.unimas.my

Abstract

Osteosarcoma is the most common primary malignancy of bone with worldwide incidence of 2 to 3 million/year. This tumour usually develops at distal part of fast growing bone and associated with instability of chromosome 6. Despite that, the preceding molecular mechanism leading to the instability is not fully known. Following the local ethical committee review, from a total of 30 cases within 7years period (from October 2008 to October 2015). The study aimed to investigate the copy number of gene encoding vascular endothelial growth factor (VEGF) located at chromosome 6p21 using Fluorescence In Situ Hybridization (FISH) and the general chromosomal instability as indicated by micronuclei formation. In addition, VEGF, Hypoxia inducible factor (HIF) and p53 diagnostic immunohistochemistry (IHC) staining were performed as to investigate relationship of hypoxic stress and tumour growth suppress. Furthermore, the mitogen activated protein kinase (MAPK) cellular proliferation pathway molecules; ERK, p38 and JNK IHC were also examined. Our findings showed VEGF expression at both protein and gene level (6p21) indicating likelihood of neovascularization. On top of that, expressed ERK, p38 but not JNK; and expressed HIF & p53 in those cases suggest tumour cell survival by evading the natural cell death program, apoptosis. In conclusion, this study presented a possible molecular mechanism underlying chromosomal instability in human osteosarcoma.

Keywords: Osteosarcoma; mitogen activated protein kinase; chromosomal instability; 6p21